House OKs Cancer Research Stamp

29 July 1997

The US House of Representatives has passed its version of a billallowing the sale of a first-class postage stamp costing pennies more that the going first-class rate, with the difference to be spent on breast cancer research.

The House bill calls for the Postal Service to determine a rate not more than 125% of the current first-class postage which, with the current 32 cent rate, would mean the stamp costing 33-40 cents. The extra 1-8 cents would go to breast cancer research, after administrative costs are deducted, with about 70% of the funds going to the National Institutes of Health and the rest to the Department of Defense, which is also doing research on the disease.

The program is voluntary, and would not replace existing first-class stamps. It would be evaluated after two years to see if is an effective fund-raising method.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight